Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis

被引：14
作者：
Maria Queralt Salas
Arjun Datt Law
Wilson Lam
Zeyad Al-Shaibani
David Loach
Dennis Dong Hwan Kim
Fotios V. Michelis
Santhosh Thyagu
Rajat Kumar
Jeffrey Howard Lipton
Jonas Mattsson
Auro Viswabandya
机构：
[1] University Health Network,Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre
来源：
Clinical Hematology International | 2019年 / 1卷 / 2期
关键词：
Haploidentical hematopoietic cell transplantation; T-cell replete grafts; Post-transplant cyclophosphamide; Anti-thymocyte globulin; Myeloid malignancies; Graft-; -host disease;
D O I：
10.2991/chi.d.190316.003
中图分类号：
学科分类号：
摘要：
Haploidentical stem cell transplantation (haploSCT) has greatly improved access to curative treatment for myeloid malignancies in patients without suitable matched sibling/unrelated donors. We investigated the safety and efficacy of haploSCT after reduced intensity conditioning (RIC) with anti-thymocyte globulin (ATG), post-transplant cyclophosphamide (PTCy), and cyclosporine to prevent rejection and graft-versus-host disease (GVHD). In this study, 47 patients received RIC using fludarabine, busulfan, and total body irradiation (200 cGy). Unmanipulated peripheral blood grafts were used. GVHD prophylaxis included ATG (4.5 mg/kg day–3 to −1), PTCy (50 mg/kg/day day +3, +4), and cyclosporine from day +5. The median follow-up was 15 months (range 3–27). Thirty one (66%) patients had acute myeloid leukemia (AML), 10 (21%) had high-risk myelodysplastic syndrome, and 6 (13%) had a myeloproliferative neoplasia. Median age was 60 years (range 22–73). The d+100 cumulative incidences of grade II–IV and III–IV acute GVHD were 17% (95% confidence interval (CI) 7.9–29.1) and 6.4% (1.6–15.9), respectively. The cumulative incidence of moderate-severe chronic GVHD at 1 year was 15.2% (95% CI 6.5–27.1). Overall survival (OS) and relapse-free survival (RFS) were 55.2% (95% CI 39.5–68.4) and 49.5% (95% CI 34.2–63), respectively. Nonrelapse mortality (NRM) for all patients at 1 year was 37.1% (95% CI 23.2–51.1). Infection was the main cause of death (26%). For AML, 1-year OS, RFS, and NRM were 64.1% (95% CI 43.3–78.9), 54.5 (95% CI 34.6–70.7), and 26.8% (95% CI 12.3–43.6), respectively. In conclusion, unmanipulated haploidentical peripheral blood stem cells (PBSC) transplantation following RIC and dual in vivo T-cell depletion results in a low incidence of acute and chronic GVHD for patients diagnosed with myeloid malignancies.
引用
收藏
页码：105 / 113
页数：8
相关论文
共 93 条
[1]  
Copelan EA(2006)Hematopoietic stem-cell transplantation N Engl J Med 354 1813-26
[2]  
Gragert L(2014)HLA match likelihoods for hematopoietic stemcell grafts in the U.S registry. N Engl J Med 371 339-48
[3]  
Eapen M(2016)On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source Biol Blood Marrow Transplant 22 410-17
[4]  
Williams E(2012)Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial Biol Blood Marrow Transplant 18 1859-66
[5]  
Freeman J(2001)Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, lowdose total body irradiation, and posttransplantation cyclophosphamide Blood 98 3456-64
[6]  
Spellman S(2014)Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft- J Clin Oncol 32 3497-505
[7]  
Baitty R(2002)-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning Biol Blood Marrow Transplant 8 377-86
[8]  
Besse K(2010)Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide Blood 115 3224-30
[9]  
Maiers M(2013)High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease J Clin Oncol 31 1310-16
[10]  
Confer D(2017)T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using posttransplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation Biol Blood Marrow Transplant 23 1555-66
12345678910